Market Research Logo

Swine Respiratory Diseases Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Swine Respiratory Diseases Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Increase in pork consumption across various regions to help lift the global swine respiratory diseases treatment market in the coming decade

Pigs are mostly affected with respiratory diseases such as PRRS (Porcine Reproductive and Respiratory Syndrome), which is a one of the common diseases. The Porcine Respiratory and Reproductive Syndrome is caused by a virus and is categorised under arterivirus. PRRS disease is also known as blue-ear pig disease. The PRRS was identified in USA during the 1980’s and is also known as the mystery swine disease. The PRRS disease is rapidly spreading in all the countries that are into pig productions, very few countries are left which are PRRS free today. The consumption of pork is increasing over the years across all the regions, which directly boosts the pork industry to produce more pork that is disease free, to enable the pork industry to meet the increasing demand for pork in the global market.

swine-respiratory-diseases-treatment-market.jpg

Market snapshot of the top regions in the global swine respiratory diseases treatment market

APEJ: APEJ is expected to lead the global swine respiratory diseases treatment market with its market size reaching a value of over US$ 1,100 Mn in 2027, growing at a CAGR 6.7%. However it is in close competition with Eastern Europe, which is leading in terms of CAGR, with a robust market growth at 6.9% CAGR during the forecast period. The animal industry is one of the fastest growing sectors in most countries of the Asia Pacific region. It is a vital industry linked to millions of jobs in related industries. However, the health and growth of this industry are being threatened by the emergence of animal diseases. APEJ’s market includes China’s pig industry, where the Chinese government is willing to invest and increase the pig industry by implementing supporting policies to support large pig farmers. Chinese scholars have indicated that they have found a new strain of PRRS virus (PRRSV) GDsg that was isolated in the Guangdong province of China, which caused high fever, high morbidity and high mortality for sow and piglets. This is helping APEJ’s swine respiratory diseases treatment market to grow exceptionally.

North America: The demand of pork in countries such as US and Canada is increasing, as a result the production of pork is increasing to meet the needs of the market. The pathogen free pork is directly contributing to the demand of the meat industry. In the pork industry in North America, especially in the U.S, most of the pork farms are using vaccines as the pork industry is looking forward to produce pork which is disease free. Vaccines are mostly used as preventive process to overcome the harmful pathogens. The use of vaccines for PRRS (porcine reproductive and respiratory syndrome) and mycoplasma is increasing, the vaccine is directly given to breeding females, to enable the new born pig to be pathogen free. The increase in use of vaccines has helped North America’s market to reach a size of over US$ 780 Mn in 2027, growing at a CAGR of 6.5% during the forecast period. Also, the market is quite positive for investors in the animal healthcare sector and it seems like a win-win situation for both the parties (investors and manufacturers) in the long term.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Swine Respiratory Treatment Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Swine respiratory diseases cause agent and effects
3.4. Regulatory Scenario
4. North America Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1.cDrivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
4.5.1. Virus
4.5.2. Mycoplasma
4.5.3. Bacteria
4.5.4. Others
4.6. Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
4.6.1. Virus
4.6.2. Mycoplasma
4.6.3. Bacteria
4.6.4. Others
4.7. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
4.7.1. Drugs
4.7.1.1. Antibiotics
4.7.1.2. Others
4.7.2. Vaccines
4.8. Market Size (US$ Mn) Forecast By Treatment Type, 2017-2027
4.8.1. Drugs
4.8.1.1. Antibiotics
4.8.1.2. Others
4.8.2. Vaccines
4.9. Historical Market Size (US$ Mn) Analysis By Route of Administration Type, 2012-2016
4.9.1. Oral
4.9.2. Parenteral
4.10.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
4.10.1. Oral
4.10.2. Parenteral
4.11.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
4.11.1. Veterinary Hospitals
4.11.2. Veterinary Clinics
4.11.3. Pharmacies
4.11.4. Others
4.12.Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
4.12.1. Veterinary Hospitals
4.12.2. Veterinary Clinics
4.12.3. Pharmacies
4.12.4. Others
4.13.Drivers and Restraints: Impact Analysis
4.14.Market Attractiveness Analysis
4.14.1. By Country
4.14.2. By Causative Agent
4.14.3. By Treatment Type
4.14.4. By Route of Administration
4.14.5. By Distribution Channel
4.15.Key Representative Market Participants
4.16.Key Participants Market Presence (Intensity Map)
5. Latin America Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
5.5.1. Virus
5.5.2. Mycoplasma
5.5.3. Bacteria
5.5.4. Others
5.6. Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
5.6.1. Virus
5.6.2. Mycoplasma
5.6.3. Bacteria
5.6.4. Others
5.7. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
5.7.1. Drugs
5.7.1.1. Antibiotics
5.7.1.2. Others
5.7.2. Vaccines
5.8. Market Size (US$ Mn) Forecast By Treatment Type, 2017-2027
5.8.1. Drugs
5.8.1.1. Antibiotics
5.8.1.2. Others
5.8.2. Vaccines
5.9. Historical Market Size (US$ Mn) Analysis By Route of Administration Type, 2012-2016
5.9.1. Oral
5.9.2. Parenteral
5.10.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
5.10.1. Oral
5.10.2. Parenteral
5.11.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
5.11.1. Veterinary Hospitals
5.11.2. Veterinary Clinics
5.11.3. Pharmacies
5.11.4. Others
5.12.Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
5.12.1. Veterinary Hospitals
5.12.2. Veterinary Clinics
5.12.3. Pharmacies
5.12.4. Others
5.13.Drivers and Restraints: Impact Analysis
5.14.Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Causative Agent
5.14.3. By Treatment Type
5.14.4. By Route of Administration
5.14.5. By Distribution Channel
5.15.Key Representative Market Participants
Key Participants Market Presence (Intensity Map)
6. Western Europe Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
6.3.1. Germany
6.3.2. UK
6.3.3. France
6.3.4. Spain
6.3.5. Italy
6.3.6. Nordic Countries
6.3.7. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1. Germany
6.4.2. UK
6.4.3. France
6.4.4. Spain
6.4.5. Italy
6.4.6. Nordic Countries
6.4.7. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
6.5.1. Virus
6.5.2. Mycoplasma
6.5.3. Bacteria
6.5.4. Others
6.6. Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
6.6.1. Virus
6.6.2. Mycoplasma
6.6.3. Bacteria
6.6.4. Others
6.7. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
6.7.1. Drugs
6.7.1.1. Antibiotics
6.7.1.2. Others
6.7.2. Vaccines
6.8. Market Size (US$ Mn) Forecast By Treatment Type, 2017-2027
6.8.1. Drugs
6.8.1.1. Antibiotics
6.8.1.2. Others
6.8.2. Vaccines
6.9. Historical Market Size (US$ Mn) Analysis By Route of Administration Type, 2012-2016
6.9.1. Oral
6.9.2. Parenteral
6.10.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
6.10.1. Oral
6.10.2. Parenteral
6.11.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
6.11.1. Veterinary Hospitals
6.11.2. Veterinary Clinics
6.11.3. Pharmacies
6.11.4. Others
6.12.Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
6.12.1. Veterinary Hospitals
6.12.2. Veterinary Clinics
6.12.3. Pharmacies
6.12.4. Others
6.13.Drivers and Restraints: Impact Analysis
6.14.Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Causative Agent
6.14.3. By Treatment Type
6.14.4. By Route of Administration
6.14.5. By Distribution Channel
6.15.Key Representative Market Participants
6.16.Key Participants Market Presence (Intensity Map)
7. Eastern Europe Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Trends
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
7.4.1. Russia
7.4.2. Poland
7.4.3. Rest of Eastern Europe
7.5. Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
7.5.1. Virus
7.5.2. Mycoplasma
7.5.3. Bacteria
7.5.4. Others
7.6. Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
7.6.1. Virus
7.6.2. Mycoplasma
7.6.3. Bacteria
7.6.4. Others
7.7. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
7.7.1. Drugs
7.7.1.1. Antibiotics
7.7.1.2. Others
7.7.2. Vaccines
7.8. Market Size (US$ Mn) Forecast By Treatment Type, 2017-2027
7.8.1. Drugs
7.8.1.1. Antibiotics
7.8.1.2. Others
7.8.2. Vaccines
7.9. Historical Market Size (US$ Mn) Analysis By Route of Administration Type, 2012-2016
7.9.1. Oral
7.9.2. Parenteral
7.10.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
7.10.1. Oral
7.10.2. Parenteral
7.11.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
7.11.1. Veterinary Hospitals
7.11.2. Veterinary Clinics
7.11.3. Pharmacies
7.11.4. Others
7.12.Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
7.12.1. Veterinary Hospitals
7.12.2. Veterinary Clinics
7.12.3. Pharmacies
7.12.4. Others
7.13.Drivers and Restraints: Impact Analysis
7.14.Market Attractiveness Analysis
7.14.1. By Country
7.14.2. By Causative Agent
7.14.3. By Treatment Type
7.14.4. By Route of Administration
7.14.5. By Distribution Channel
7.15.Key Representative Market Participants
7.16.Key Participants Market Presence (Intensity Map)
8. Asia Pacific Excluding Japan Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) and Analysis By Country, 2012-2016
8.3.1. China
8.3.2. Philippine
8.3.3. South Korea
8.3.4. India
8.3.5. Australia
8.3.6. Rest of Asia Pacifc
8.4. Market Size (US$ Mn) and Forecast By Country, 2017-2027
8.4.1. China
8.4.2. Philippine
8.4.3. South Korea
8.4.4. India
8.4.5. Australia
8.4.6. Rest of Asia Pacifc
8.5. Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
8.5.1. Virus
8.5.2. Mycoplasma
8.5.3. Bacteria
8.5.4. Others
8.6. Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
8.6.1. Virus
8.6.2. Mycoplasma
8.6.3. Bacteria
8.6.4. Others
8.7. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
8.7.1. Drugs
8.7.1.1. Antibiotics
8.7.1.2. Others
8.7.2. Vaccines
8.8. Market Size (US$ Mn) Forecast By Treatment Type, 2017-2027
8.8.1. Drugs
8.8.1.1. Antibiotics
8.8.1.2. Others
8.8.2. Vaccines
8.9. Historical Market Size (US$ Mn) Analysis By Route of Administration Type, 2012-2016
8.9.1. Oral
8.9.2. Parenteral
8.10.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
8.10.1. Oral
8.10.2. Parenteral
8.11.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
8.11.1. Veterinary Hospitals
8.11.2. Veterinary Clinics
8.11.3. Pharmacies
8.11.4. Others
8.12.Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
8.12.1. Veterinary Hospitals
8.12.2. Veterinary Clinics
8.12.3. Pharmacies
8.12.4. Others
8.13.Drivers and Restraints: Impact Analysis
8.14.Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Causative Agent
8.14.3. By Treatment Type
8.14.4. By Route of Administration
8.14.5. By Distribution Channel
8.15.Key Representative Market Participants
8.16.Key Participants Market Presence (Intensity Map)
9. Japan Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Japan Market Dynamics
9.2.1. Drivers
9.2.2. Restraints
9.2.3. Trends
9.3. Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
9.3.1. Virus
9.3.2. Mycoplasma
9.3.3. Bacteria
9.3.4. Others
9.4. Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
9.4.1. Virus
9.4.2. Mycoplasma
9.4.3. Bacteria
9.4.4. Others
9.5. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
9.5.1. Drugs
9.5.1.1. Antibiotics
9.5.1.2. Others
9.5.2. Vaccines
9.6. Market Size (US$ Mn) Forecast By Treatment Type, 2017-2027
9.6.1. Drugs
9.6.1.1. Antibiotics
9.6.1.2. Others
9.6.2. Vaccines
9.7. Historical Market Size (US$ Mn) Analysis By Route of Administration Type, 2012-2016
9.7.1. Oral
9.7.2. Parenteral
9.8. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
9.8.1. Oral
9.8.2. Parenteral
9.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
9.9.1. Veterinary Hospitals
9.9.2. Veterinary Clinics
9.9.3. Pharmacies
9.9.4. Others
9.10.Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
9.10.1. Veterinary Hospitals
9.10.2. Veterinary Clinics
9.10.3. Pharmacies
9.10.4. Others
9.11.Drivers and Restraints: Impact Analysis
9.12.Market Attractiveness Analysis
9.12.1. By Causative Agent
9.12.2. By Treatment Type
9.12.3. By Route of Administration
9.12.4. By Distribution Channel
9.13.Key Representative Market Participants
9.14.Key Participants Market Presence (Intensity Map)
10. Middle East and Africa Swine Respiratory Treatment Market Analysis 2012–2016 and Forecast 2017–2027
10.1.Introduction
10.2.Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3.Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of Middle East and Africa
10.4.Market Size (US$ Mn) Forecast By Country, 2017-2027
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of Middle East and Africa
10.5.Historical Market Size (US$ Mn) Analysis By Causative Agent, 2012-2016
10.5.1. Virus
10.5.2. Mycoplasma
10.5.3. Bacteria
10.5.4. Others
10.6.Market Size (US$ Mn) Forecast By Causative Agent, 2017-2027
10.6.1. Virus
10.6.2. Mycoplasma
10.6.3. Bacteria
10.6.4. Others
10.7.Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012-2016
10.7.1. Drugs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report